KSHV microRNAs in tumor invasion and angiogenesis
KSHV microRNA 在肿瘤侵袭和血管生成中的作用
基本信息
- 批准号:9243868
- 负责人:
- 金额:$ 20万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-03-03 至 2022-02-28
- 项目状态:已结题
- 来源:
- 关键词:ADRBK1 geneAcquired Immunodeficiency SyndromeBindingCellsChinaClinical TrialsDevelopmentEtiologyFundingG protein coupled receptor kinaseGenomeGlutamic AcidGoalsHerpesviridae InfectionsHighly Active Antiretroviral TherapyHumanHuman Herpesvirus 8IndividualKaposi SarcomaLaboratoriesMalignant - descriptorMalignant NeoplasmsMediatingMesenchymal Stem CellsMicroRNAsModelingMolecularMorbidity - disease rateMulticentric Angiofollicular Lymphoid HyperplasiaMutagenesisMutateOrganPathologicPathway interactionsPatientsPreventionProteinsProto-Oncogene Proteins c-aktRoleSH3 DomainsSTAT3 geneSignal TransductionSiteSocietiesTherapeuticTimeTumor AngiogenesisTumor Cell InvasionViralVisceralangiogenesiscellular targetinginhibitor/antagonistinnovationinsightmortalitynovelnovel therapeutic interventionoverexpressionprimary effusion lymphomaprogramstherapeutic targettumortumorigenesis
项目摘要
Kaposi’s sarcoma-associated herpesvirus (KSHV) is the etiologic agent of several cancers. Despite highly
active anti-retroviral therapy, Kaposi’s sarcoma (KS) remains as a dominant cancer in AIDS patients. The
hallmark pathological features of KS are excessive deregulation of angiogenesis and extreme invasiveness
manifested as multifocal tumors and involvement of visceral organs. Thus, understanding the molecular basis
of KSHV-induced angiogenesis and cell invasion could serve as the basis for developing novel therapeutic
approaches. Our US-China collaborative team funded by previous cycle of the US-China Program has made
significant progresses toward this goal by 1) developing a novel model of KSHV infection of human primary
mesenchymal stem cells (MSCs), in which KSHV induces angiogenesis, cell invasion, malignant
transformation and tumorigenesis closely mimicking human KS tumors;; 2) demonstrating the essential roles of
KSHV microRNAs (miRNAs) in KSHV-induced angiogenesis and cell invasion;; 3) identifying KSHV miR-K6-3p
as a pro-angiogenic miRNA that induces angiogenesis by targeting SH3 domain-binding glutamic acid-rich
protein (SH3BGR) to activate the STAT3 pathway;; and 4) demonstrating that KSHV miR-K3-5p promotes cell
invasion by targeting G-protein coupled receptor kinase 2 (GRK2) to activate the AKT signaling. We propose to
extend these exciting discoveries with the objective to further dissect the molecular mechanisms by which
KSHV miRNAs promote tumorigenesis by inducing angiogenesis and cell invasion, and to explore the
therapeutic application of these discoveries. The central hypothesis is that KSHV encodes specific miRNAs
to activate angiogenic and invasive pathways contributing to KSHV-induced tumorigenesis, and as a result,
targeting these pathways can effectively inhibit the development of KSHV-induced cancers. We will identify
KSHV miRNAs that mediate KSHV-induced angiogenesis and define the mechanisms of action (Aim 1);;
identify KSHV miRNAs that mediate KSHV-induced cell invasion and define the mechanisms of action (Aim 2);;
delineate the roles of pro-angiogenic and pro-invasive miRNAs in the development of tumors, and in tumor
angiogenesis and invasion (Aim 3);; and explore the therapeutic application of targeting angiogenic and
invasive pathways activated by KSHV miRNAs in KSHV-induced tumorigenesis (Aim 4). This application will
further reinforce the collaborative efforts of the two US and China teams with highly complementary expertise
to accelerate the advancements of the proposed project that are otherwise difficult to achieve by the individual
laboratories. The results from this project will be highly significant and innovative because they will, for the
first time, define the functions and mechanisms of action of KSHV miRNAs in tumor angiogenesis and invasion
in a genuine KS model, and identify novel targets for developing innovative therapeutic approaches. The study
will also establish a novel paradigm of oncogenesis mediated by viral subversion of the miRNA pathway, thus
providing insights into the oncogenesis of other cancers.
卡波西肉瘤相关疱疹病毒(KSHV)是几种癌症的病原体。
尽管积极的抗逆转录病毒治疗,卡波西肉瘤(KS)仍然是艾滋病患者的主要癌症。
KS的标志性病理特征是过度的血管生成失调和极端的侵袭性
表现为多灶性肿瘤并累及内脏器官。因此,了解其分子基础
KSHV-1诱导的血管生成和细胞侵袭可以作为开发新的治疗方法的基础。
我们的美中合作团队由上一轮美中项目资助,
通过1)开发KSHV感染人原发性肝癌的新模型,
间充质干细胞(MSC),其中KSHV诱导血管生成,细胞侵袭,恶性
转化和肿瘤发生密切模仿人类KS肿瘤; 102)证明的基本作用,
KSHV microRNAs(miRNAs)在KSHV-miR-3 K6诱导的血管生成和细胞侵袭中的作用;
作为一种促血管生成的miRNA,通过靶向SH 3结构域结合富含谷氨酸的
蛋白(SH 3BGR)激活STAT 3通路; 4)证明KSHV miR-PK 3-PK 5 p促进细胞增殖,
通过靶向G-κ B蛋白偶联受体激酶2(GRK 2)激活AKT信号转导来抑制细胞侵袭。
扩展这些令人兴奋的发现,目的是进一步剖析分子机制,
KSHV miRNAs通过诱导血管生成和细胞侵袭促进肿瘤发生,并探讨其在肿瘤发生中的作用。
这些发现的治疗应用。中心假设是KSHV编码特定的miRNAs,
激活血管生成和侵袭途径,从而促进KSHV-HBV诱导的肿瘤发生,结果,
靶向这些通路可以有效抑制KSHV-HBV诱导的癌症的发展。
介导KSHV-1诱导的血管生成并定义作用机制的KSHV miRNAs(Aim 1);
鉴定介导KSHV-1诱导的细胞侵袭的KSHV miRNAs,并确定其作用机制(目的2);
描述了促血管生成和促侵袭性miRNA在肿瘤发生中的作用,
血管生成和侵袭(Aim 3),探讨靶向血管生成和侵袭的治疗应用。
在KSHV-miRNA诱导的肿瘤发生中由KSHV-miRNA激活的侵袭途径(目的4)。
进一步加强中美两个具有高度互补专业知识的团队的合作努力
加速推进个人难以实现的拟议项目
该项目的结果将是非常重要的和创新的,因为它们将,
首次明确了KSHV miRNAs在肿瘤血管生成和侵袭中的功能和作用机制
在一个真正的KS模型,并确定新的目标,开发创新的治疗方法。
还将建立一种新的由病毒破坏miRNA途径介导的肿瘤发生模式,
为其他癌症的发生提供了新的见解。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Shou-Jiang Gao其他文献
Shou-Jiang Gao的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Shou-Jiang Gao', 18)}}的其他基金
Citrulline-urea cycle in KSHV cellular transformation
KSHV 细胞转化中的瓜氨酸-尿素循环
- 批准号:
10634838 - 财政年份:2023
- 资助金额:
$ 20万 - 项目类别:
Impact of microbiota on AIDS-Kaposi’s sarcoma development and therapy
微生物群对艾滋病-卡波西肉瘤发展和治疗的影响
- 批准号:
10753890 - 财政年份:2023
- 资助金额:
$ 20万 - 项目类别:
Regulation of KSHV replication by N6-methyladenosine (m6A) - Diversity Supplement
N6-甲基腺苷 (m6A) 对 KSHV 复制的调节 - Diversity Supplement
- 批准号:
10533427 - 财政年份:2022
- 资助金额:
$ 20万 - 项目类别:
HISTONE MODIFIERS IN ORAL KSHV INFECTION AND MALIGNANCIES
口腔 KSHV 感染和恶性肿瘤中的组蛋白修饰剂
- 批准号:
9756364 - 财政年份:2018
- 资助金额:
$ 20万 - 项目类别:
KSHV microRNAs in tumor invasion and angiogenesis
KSHV microRNA 在肿瘤侵袭和血管生成中的作用
- 批准号:
10264784 - 财政年份:2017
- 资助金额:
$ 20万 - 项目类别:
KSHV microRNAs in tumor invasion and angiogenesis
KSHV microRNA 在肿瘤侵袭和血管生成中的作用
- 批准号:
9906178 - 财政年份:2017
- 资助金额:
$ 20万 - 项目类别:
Targeting KSHV malignancies and persistent infection
针对 KSHV 恶性肿瘤和持续感染
- 批准号:
8943348 - 财政年份:2015
- 资助金额:
$ 20万 - 项目类别:
HISTONE MODIFIERS IN ORAL KSHV INFECTION AND MALIGNANCIES
口腔 KSHV 感染和恶性肿瘤中的组蛋白修饰剂
- 批准号:
9257374 - 财政年份:2015
- 资助金额:
$ 20万 - 项目类别:
HISTONE MODIFIERS IN ORAL KSHV INFECTION AND MALIGNANCIES
口腔 KSHV 感染和恶性肿瘤中的组蛋白修饰剂
- 批准号:
9108377 - 财政年份:2015
- 资助金额:
$ 20万 - 项目类别:
KSHV microRNAs in cellular transformation and tumorigenesis
KSHV microRNA 在细胞转化和肿瘤发生中的作用
- 批准号:
8728172 - 财政年份:2013
- 资助金额:
$ 20万 - 项目类别:
相似海外基金
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
- 批准号:
10219039 - 财政年份:2020
- 资助金额:
$ 20万 - 项目类别:
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
- 批准号:
9981476 - 财政年份:2019
- 资助金额:
$ 20万 - 项目类别:
IGF::OT::IGF RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
IGF::OT::IGF 针对获得性免疫缺陷综合症分类的研究支持服务
- 批准号:
9364184 - 财政年份:2016
- 资助金额:
$ 20万 - 项目类别:
Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) in Saskatchewan- Where are we now and what does the future hold?
萨斯喀彻温省的人类免疫缺陷病毒(HIV)和获得性免疫缺陷综合症(艾滋病)——我们现在在哪里以及未来会怎样?
- 批准号:
236932 - 财政年份:2011
- 资助金额:
$ 20万 - 项目类别:
Miscellaneous Programs
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
- 批准号:
3554155 - 财政年份:1991
- 资助金额:
$ 20万 - 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
- 批准号:
3554156 - 财政年份:1991
- 资助金额:
$ 20万 - 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW
获得性免疫缺陷综合症研究综述
- 批准号:
2063342 - 财政年份:1991
- 资助金额:
$ 20万 - 项目类别: